Physician profile
Laya Nasrollah
NPI 1558673566
$957.81
in general payments reported to CMS, 2019-2025
14 companies · $181 in 2025
The $181 reported for 2025 was less than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $255 · 2020: $11.11 · 2021: $42.09 · 2022: $60.02 · 2023: $155 · 2024: $254 · 2025: $181.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $572 · Education: $17.27.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $572.14 |
| Education | $17.27 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $316.18 | 2019-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $124.65 | 2019-2023 | Xifaxan |
| Mindray Ds USA, INC. | $118.84 | 2024 | Patient Monitor, Na Electrode,Indirect,International |
| Genzyme Corporation | $91.17 | 2024-2025 | |
| Celltrion USA INC. | $77.06 | 2024-2025 | Vegzelma, Zymfentra |
| Janssen Biotech, INC. | $76.44 | 2019-2025 | Tremfya |
| Gilead Sciences, INC. | $49.02 | 2019-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $35.32 | 2019-2023 | Entyvio |
| Regeneron Healthcare Solutions, INC. | $20.80 | 2023 | Dupixent |
| Shionogi INC | $12.38 | 2019 | |
| Glaxosmithkline, LLC. | $12.18 | 2019 | |
| Novo Nordisk INC | $11.64 | 2019 | |
| Alfasigma USA, INC. | $11.11 | 2020 | |
| Travere Therapeutics, INC. | $1.02 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Laya Nasrollah listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.